Author

M. Dreyling

h-index 12 View on Semantic Scholar

We have 3 of 83 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

For patients with large B-cell lymphoma progressing after multiple lines of therapy few treatment options remain, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers...

Evgenii Shumilov, Lina J. Kolloch, Philipp Faustmann et al. · Blood Advances · 0 citations

Open access Aug 2026

Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020–2022

Patients with malignant lymphomas are at increased risk for severe COVID-19. In the general population, outcomes of COVID-19 have improved dramatically over time due to increasing immunity through vaccination or infection and due to improved clinical care. It is unclear whether outcomes of COVID-19 in patients with lym...

Stefanie Forkl, Felix Freudenberger, Benedikt Jacobs et al. · Annals of Hematology · 0 citations

Clinical trial Sep 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

This phase 1 dose-escalation part of the ATALANTA-1 phase 1/2, single-arm study was executed in five hospitals in the Netherlands and Belgium to evaluate the safety and determine the recommended phase 2 dose of GLPG5101.

M. Kersten, M. Kuipers, P. Mutsaers et al. · The Lancet Haematology · 0 citations